The elevated hippurate levels in the serum of HSD-fed tumor-bearing mice corroborated with the previously published report on Hippurate as a metabolic biomarker for the cancer patients that responded well to anti-PD1 immunotherapy (21). This evidence concerns the gene RPL17 and cancer.